
Recursion Pharmaceuticals, Inc. (RXRX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreNews headlines
Powered by Yahoo ScoutRecursion Pharmaceuticals reported Q3 2026 revenue of $18.6 million, a $119 million net loss, and clinical progress for REC-4881 and REC-1245. The company also raised financing, extending its projected cash runway into 2029, while shares gained 8.24% on November 9based on the regular session plus after-hours trading. The main debate remains whether clinical advances and partnerships can offset ongoing losses and dilution risk.







